%0 Journal Article
%T Afatinib with subsequent surgery in stage III NSCLC with EGFR mutation: Lessons learned from two clinical experiences
%A Francesca Mazzoni
%A Francesco Di Costanzo
%A Lorenzo Livi
%A Luca Voltolini
%A Marco Perna
%A Paolo Petreni
%A Stefano Bongiolatti
%A Vieri Scotti
%J Tumori Journal
%@ 2038-2529
%D 2018
%R 10.1177/0300891618775204
%X Afatinib, a second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is effective as first-line treatment in patients with EGFR-mutated non-small cell lung cancer (NSCLC). We report 2 cases of EGFR-mutated locally advanced NSCLC treated in neoadjuvant setting with EGFR tyrosine kinase inhibitor at University of Florence/Careggi Hospital. In both cases, afatinib was used for up to 3 months, until 1 week before surgery. Both patients achieved significant reduction (downstaging) of the pulmonary mass and lymphadenopathies and after surgery, it was decided for both cases to restore afatinib treatment up to a further 4 months. Both patients experienced local and distant disease relapses after 9 and 10 months, respectively, and then we restored the afatinib treatment
%K Non-small cell lung cancer
%K afatinib
%K neo-adjuvant
%K EGFR
%U https://journals.sagepub.com/doi/full/10.1177/0300891618775204